Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prevention Gets $10 Billion Boost In Add-On To Senate Reform Bill

This article was originally published in The Gray Sheet

Executive Summary

Health screenings for common diseases and pandemic illnesses such as H1N1 influenza would get a funding boost under a health reform bill amendment approved June 23 by the Senate Health, Education, Labor, and Pensions Committee

You may also be interested in...



Friendly Fire? Tavenner Nomination Held Up By Sen. Harkin

While the Senate Finance Committee April 23 agreed to endorse Marilyn Tavenner to head CMS, Sen. Tom Harkin, D-Iowa, Chairman of the Senate HELP Committee, put a block on her full Senate approval the next day.

GOP Attacks Center On Budget Office Scoring At Health Reform Mark-Up

Senate Republicans launched a full-scale attack on Democratic health care reform bills last week, taking advantage of preliminary Congressional Budget Office cost estimates to make the case for at least delaying legislation from moving through committee

Most States Still Lack ‘Sentinel Labs’ For Pandemic Flu Testing – OIG Report

Most states - 44 out of 50, plus the District of Columbia - still have no sentinel lab capability to detect influenza A subtype H5, the avian flu virus that could lead to pandemic flu, despite $350 million appropriated by Congress in 2005 to help prepare for this potential catastrophe, says the HHS Office of Inspector General

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel